Malenka Robert C. 4

What Happened
Robert C. Malenka, a director of MapLight Therapeutics, sold 12,116 shares of the company's common stock in an open-market sale on February 13, 2026. The weighted-average price reported was $18.21 per share, generating proceeds of about $220,632. The filing indicates these sales were made to cover tax obligations related to the settlement of restricted stock units (RSUs).

Key Details

• Transaction date: 2026-02-13 (reported on Form 4 filed 2026-02-18). The filing was timely (within two business days).
• Transaction type/code: Sale (S).
• Shares sold: 12,116 shares; weighted-average price: $18.21; total proceeds: $220,632.
• Price range: shares were sold in multiple transactions at prices from $18.00 to $18.59; the $18.21 is the weighted average.
• Reason noted: Sales were to cover tax withholding on RSU settlement (common practice).
• Holdings/ownership: Shares are held by the Robert C. Malenka Living Trust (Reporting Person is sole trustee with voting/dispositive power). The filing does not state the total shares owned following the sale.
• Lock-up/other restriction: The filing notes retained securities remain subject to a 180-day IPO lock-up (final prospectus dated Oct 26, 2025), through roughly April 24, 2026.

Context
Sales to cover tax withholding on RSU settlements are routine and often do not indicate a change in the insider’s view of the company. This was a disposal, not a purchase or exercise; therefore it is typically less informative about insider sentiment than buys. If you want a fuller picture, compare this sale to other recent insider transactions and the insider’s remaining holdings (not specified here).